Kodiak Sciences Inc. (Nasdaq: KOD) announced it has completed enrollment of the first 300-patient cohort in its Phase 3 PEAK ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE